WALNUT CREEK, California – (BUSINESS WIRE) – DayTwo, a leader in precision medicine with the world’s largest, highest-resolution microbiome discovery platform, announced today that it has introduced a unique way to treat depression in people with diabetes. The new solution, called EATS ™ (Engage, Assess, Transition, Support) uses psychological techniques to overcome emotional barriers to managing chronic illnesses.
The model was developed by the DayTwo clinical team, which includes staff psychologists, behavioral researchers and gastroenterologists with expertise in the intestinal / brain axis. Depression and diabetes have a two-way relationship that can affect each other. Diabetes can lead to depression, and depression can lead to diabetes. According to the CDC, approximately 30% of people with diabetes experience symptoms of depression.
With EATS ™, DayTwo has reinvented the metabolic disease management model by incorporating a unique approach to mental health. This is likely to lead to even higher engagement rates and improve the already outstanding results of the DayTwo program. DayTwo’s protocol is based on science using microbiome profiles and a unique artificial intelligence-based algorithm that has found that people react differently to the same food. In addition, the blood sugar response to foods and food combinations varies from person to person based on each individual’s individual microbiome. This is a completely different approach than traditional population health programs, which typically focus on surveillance, a standardized diet, or a carbohydrate elimination diet.
In May 2021, DayTwo showcased the science behind the gut-brain connection at the Health Action Council (HAC), which represents major employers working to improve human and economic health. HAC represents more than 220 employers and union groups covering over 2.6 million unique lives.
“We are excited to announce our new approach to behavior change as part of our award-winning Diabetes and Metabolic Diseases Program during Mental Health Awareness Month,” said Josh Stevens, President of DayTwo. “Metabolic diseases have both psychological and physiological dimensions. Our members benefit from both precision nutrition and behavioral research. ”
Watch them HAC presentation here.
ABOUT DAYTWO
DayTwo, a leading provider of precision medicine with the world’s largest and highest-resolution platform for the discovery of microbiomes, offers a sustainable path to remission from metabolic diseases (diabetes, prediabetes, clinical obesity, non-alcoholic fatty liver diseases).
DayTwo’s Metabolic Disease Solution improves health outcomes and reduces or eliminates prescription medication by improving reach and lowering A1C through gut microbiome profiling, artificial intelligence and dedicated virtual care.
Metabolic disease is the first condition treated by DayTwo’s microbiome discovery platform. Together with artificial intelligence and dedicated virtual care, it offers an engaging and effective care plan for chronic diseases.
To learn more about DayTwo and its solutions to chronic diseases, visit www.daytwo.com.
